Citigroup’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1
| Closed | -$4 | – | 6120 |
|
|
2025
Q3 | $4 | Buy |
+1
| New | +$7 | ﹤0.01% | 5991 |
|
|
2023
Q1 | – | Sell |
-50
| Closed | -$842 | – | 5545 |
|
|
2022
Q4 | $842 | Buy |
50
+2
| +4% | +$36 | ﹤0.01% | 5431 |
|
|
2022
Q3 | $1K | Sell |
48
-13
| -21% | -$285 | ﹤0.01% | 5612 |
|
|
2022
Q2 | $1K | Sell |
61
-63
| -51% | -$1.53K | ﹤0.01% | 5992 |
|
|
2022
Q1 | $4K | Sell |
124
-534
| -81% | -$16K | ﹤0.01% | 5880 |
|
|
2021
Q4 | $27K | Buy |
658
+431
| +190% | +$27.9K | ﹤0.01% | 5304 |
|
|
2021
Q3 | $20K | Buy |
+227
| New | +$20K | ﹤0.01% | 5230 |
|
|
2020
Q2 | – | Sell |
-256
| Closed | -$7K | – | 7552 |
|
|
2020
Q1 | $7K | Buy |
256
+46
| +22% | +$1.7K | ﹤0.01% | 7154 |
|
|
2019
Q4 | $9K | Hold |
210
| – | – | ﹤0.01% | 7232 |
|
|
2019
Q3 | $2K | Sell |
210
-71
| -25% | -$1.02K | ﹤0.01% | 7528 |
|
|
2019
Q2 | $4K | Sell |
281
-224
| -44% | -$4K | ﹤0.01% | 7520 |
|
|
2019
Q1 | $10K | Buy |
505
+16
| +3% | +$318 | ﹤0.01% | 7247 |
|
|
2018
Q4 | $7K | Sell |
489
-23
| -4% | -$1.08K | ﹤0.01% | 7261 |
|
|
2018
Q3 | $47K | Buy |
512
+508
| +12,700% | +$60.4K | ﹤0.01% | 6565 |
|
|
2018
Q2 | $1K | Sell |
4
-193
| -98% | -$32.5K | ﹤0.01% | 7516 |
|
|
2018
Q1 | $31K | Buy |
197
+180
| +1,059% | +$21.9K | ﹤0.01% | 6480 |
|
|
2017
Q4 | $2K | Sell |
17
-41
| -71% | -$4.4K | ﹤0.01% | 7378 |
|
|
2017
Q3 | $8K | Buy |
58
+43
| +287% | +$5.25K | ﹤0.01% | 6739 |
|
|
2017
Q2 | $2K | Sell |
15
-123
| -89% | -$14.8K | ﹤0.01% | 6969 |
|
|
2017
Q1 | $17K | Sell |
138
-510
| -79% | -$60.2K | ﹤0.01% | 6328 |
|
|
2016
Q4 | $87K | Buy |
648
+601
| +1,279% | +$151K | ﹤0.01% | 5853 |
|
|
2016
Q3 | $12K | Buy |
+47
| New | +$5.76K | ﹤0.01% | 6448 |
|
Other funds holding CLSD
Citigroup's CLSD Position: Q4 2025 in Review
Citigroup sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 1 share — an estimated $4 sold.
Citigroup first reported a position in CLSD in Q3 2016 and held it in 22 quarters. The position peaked at $87K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- Citigroup reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- Citigroup sold 1 Clearside Biomedical share in Q4 2025, an estimated $4.
- Citigroup first reported a position in Clearside Biomedical in Q3 2016 and held it in 22 quarters.
- Citigroup's Clearside Biomedical position peaked at $87K in Q4 2016.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.